Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conformational Abs recognizing a generic amyloid fibril epitope.

Brian O'Nuallain1, Ronald Wetzel

  • 1Graduate School of Medicine, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA.

Proceedings of the National Academy of Sciences of the United States of America
|January 31, 2002
PubMed
Summary

Researchers developed conformation-specific antibodies that bind to amyloid fibrils in Alzheimer's disease and other amyloid conditions. These antibodies target a common structural motif, aiding in understanding and potentially treating amyloid diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth.

Cancers·2024
Same author

A Targetable Self-association Surface of the Huntingtin exon1 Helical Tetramer Required for Assembly of Amyloid Pre-nucleation Oligomers.

Journal of molecular biology·2024
Same author

PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages.

Cancer research communications·2023
Same author

Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington's disease.

Acta neuropathologica communications·2021
Same author

Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites.

Acta neuropathologica·2021
Same author

Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.

Accounts of chemical research·2020

Area of Science:

  • Biochemistry
  • Immunology
  • Neuroscience

Background:

  • Amyloid fibrils are implicated in various diseases, including Alzheimer's.
  • The precise structure and commonalities among disease-related amyloid fibrils remain poorly understood.
  • Existing antibodies often lack specificity for the fibrillar state of amyloid proteins.

Purpose of the Study:

  • To generate and characterize conformation-specific monoclonal antibodies (mAbs) targeting amyloid fibrils.
  • To investigate if these mAbs recognize a common structural feature across different amyloid types.
  • To explore the potential diagnostic and therapeutic applications of these novel antibodies.

Main Methods:

  • Generation and characterization of two conformation-specific mAbs, WO1 and WO2.

Related Experiment Videos

  • Testing antibody binding against Alzheimer's peptide A beta(1-40) in fibril and monomeric states.
  • Assessing antibody cross-reactivity with amyloid fibrils from transthyretin, islet amyloid polypeptide, beta(2)-microglobulin, and polyglutamine.

    • Main Results:

    • WO1 and WO2 specifically bind to the amyloid fibril state of A beta(1-40), not its soluble form.
    • These antibodies also bind to diverse disease-related amyloid fibrils and aggregates of unrelated proteins.
    • Antibody binding is independent of native protein precursors and other protein aggregates, suggesting recognition of a shared conformational epitope.

    Conclusions:

    • A common amyloid-folding motif exists across various disease-related amyloids.
    • Conformation-specific antibodies like WO1 and WO2 can recognize this shared epitope.
    • These antibodies represent valuable tools for understanding amyloid structure, assembly, and toxicity, and for developing diagnostics and therapeutics for amyloid diseases.